Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients
Author:
Denisenko Natalia P.12ORCID, Kachanova Anastasia A.3ORCID, Sychev Ivan V.4ORCID, Shuev Gregory N.3ORCID, Perfilieva Oksana M.3, Mukhamadiev Reis H.3ORCID, Kazakov Ruslan E.3ORCID, Milyutina Olga I.3ORCID, Konenkova Olga V.3ORCID, Ryzhkin Sergey A.3ORCID, Zhmaeva Elena M.3, Kirienko Sergey L.3, Ivashchenko Dmitriy V.12ORCID, Bure Irina V.12ORCID, Ametov Alexander S.3, Poddubnaya Irina V.3ORCID, Mirzaev Karin B.12ORCID, Sychev Dmitry A.3ORCID
Affiliation:
1. Research Laboratory of Neuroendocrine Tumors , Centre for Personalized Medicine , Saint-Petersburg , Russia 2. Research Institute of Molecular and Personalized Medicine , Russian Medical Academy of Continuous Professional Education , Moscow , Russia 3. Russian Medical Academy of Continuous Professional Education , Moscow , Russia 4. Department of Faculty Therapy with courses of Physiotherapy and Exercise Therapy, Medicine Institute , Ogarev Mordovia State University , Saransk , Russia
Abstract
Abstract
Objectives
Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients.
Methods
The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. NFKB1, ATM, ATG16L2, ATG10, TGFB1, and TNF polymorphisms were determined by allele-specific realtime-PCR.
Results
The frequency of adverse reactions was the following: gastrointestinal symptoms – 57.9 %, local symptoms – 65.8 %, cerebral symptoms – 46.8 %, fatigue – 54.4 %; signs of sialoadenitis six months after radioiodine therapy – 25.2 %. TT genotype carriers of ATG10 rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of ATG10 rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of TGFB1 rs1800469 (vs. AG+GG). CC genotype of ATG10 rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the ATM rs11212570 had a protective role against fatigue. TGFB1 rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy.
Conclusions
Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.
Publisher
Walter de Gruyter GmbH
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference48 articles.
1. Haddad, RI, Bischoff, L, Ball, D, Bernet, V, Blomain, E, Busaidy, NL, et al.. Thyroid carcinoma, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2022;20:925–51. https://doi.org/10.6004/jnccn.2022.0040. 2. Smanik, PA, Liu, Q, Furminger, TL, Ryu, K, Xing, S, Mazzaferri, EL, et al.. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339–45. https://doi.org/10.1006/bbrc.1996.1358. 3. Levy, O, De la Vieja, A, Carrasco, N. The Na+/I- symporter (NIS): recent advances. J Bioenerg Biomembr 1998;30:195–206. https://doi.org/10.1023/a:1020577426732. 4. Solans, R, Bosch, JA, Galofré, P, Porta, F, Roselló, J, Selva-O’Callagan, A, et al.. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738–43. 5. Chung, J-K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43:1188–200.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|